Filing Flows › Upstream Bio (UPB) › Q2 2026
Upstream Bio (UPB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Upstream Bio (UPB) reported revenue of $773K for the second quarter 2026 (Q2 2026), -18% from a year earlier and -25% from the quarter before.
Upstream Bio, Q2 2026: revenue $773K (-18% year over year), net loss $39.7M, operating cash flow −$35.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $773K | -25% | -18% |
| Operating profit | −$42.4M | — | — |
| Net earnings | −$39.7M | — | — |
| Operating cash flow | −$35.6M | — | — |
What changed
Revenue was $773K in Q2 2026, down 18% year over year and down 25% from the previous quarter.
Operating costs exceeded revenue by $42.4M, an operating margin of -5481.0%. Total costs fell 5% while revenue fell 18%. The quarter ended with a net loss of $39.7M, narrower than the previous quarter's $40.6M loss.
Operating cash flow was −$35.6M. Non-cash charges added back $50K of depreciation and amortization and $4.4M of share-based compensation.
Questions
What was Upstream Bio's revenue in the second quarter 2026?
Upstream Bio (UPB) reported revenue of $773K for the second quarter 2026 (Q2 2026), -18% from a year earlier and -25% from the quarter before.
Source: Upstream Bio 10-Q on SEC EDGAR.